The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities
Official Title: A Multicenter, Single Arm, Non-Interventional, Observational Study of Obinutuzumab to Evaluate Efficacy, Safety and Cost of Disease Management in Patients With Chronic Lymphocytic Leukemia and Comorbidities in Greece
Study ID: NCT02915224
Brief Summary: This multicenter, single arm, non-interventional, observational study will evaluate the efficacy and safety of obinutuzumab in daily clinical practice in participants with chronic lymphocytic leukemia (CLL). The study will also assess cost of disease management. The total length of the study is 42 months.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University General Hospital of Alexandroupolis; Haemotology, Alexandroup, , Greece
Laiko General Hospital of Athens; A Propedeutical Clinic of Internal Medicine, Athens, , Greece
Laiko General Hospital; Hematology Clinic, Athens, , Greece
General Hospital G. Gennimatas; Hematology Dept., Athens, , Greece
Attiko Hospital; Haematology Clinic, Athens, , Greece
Periph. University General Hospital of Heraklion; Hematology, Heraklion, , Greece
University Hospital of Larissa; Hematology Dept., Larissa, , Greece
University General Hospital of Patra; Internal Medicine Clinic - Hematology Department, Patra, , Greece
Metaxa Hospital; Hematology Clinic, Peiraias, , Greece
AXEPA Pathology Section; A Pathology Clinic, Thessaloniki, , Greece
General Hospital G. Papanikolaou; Hematology, BMT Unit, Thessaloniki, , Greece
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR